Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines

Authors: Naohisa Takaoka, Tatsuya Takayama, Seiichiro Ozono

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Renal cell carcinomas (RCCs) overexpress fatty acid binding protein 7 (FABP7). We chose to study the TUHR14TKB cell line, because it expresses higher levels of FABP7 than other cell lines derived from renal carcinomas (OS-RC-2, 786-O, 769-P, Caki-1, and ACHN).

Methods

FABP7 expression was detected using western blotting and real-time PCR. Cell proliferation was determined using an MTS assay and by directly by counting cells. The cell cycle was assayed using flow cytometry. Cell migration was assayed using wound-healing assays. An FABP7 expression vector was used to transfect RCC cell lines.

Results

The levels of FABP7 expressed by TUHR14TKB cells and their doubling times decreased during passage. High-passage TUHR14TKB cells comprised fewer G0/G1-phase and more S-phase cells than low-passage cells. Cell proliferation differed among subclones isolated from cultures of low-passage TUHR14TKB cells. The proliferation of TUHR14TKB cells decreased when FABP7 was overexpressed, and the cell migration property of TUHR14TKB cells were decreased when FABP7 was overexpressed. High concentrations of docosatetraenoic acid and eicosapentaenoic acid accumulated in TUHR14TKB cells that overexpressed FABP7, and docosatetraenoic acid enhanced cell proliferation.

Conclusions

The TUHR14TKB cell line represents a heterogeneous population that does not express FABP7 when it rapidly proliferates. The differences in FABP7 function between RCC cell lines suggests that FABP7 affects cell proliferation depending on cell phenotype.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
3.
go back to reference Pastore AL, Palleschi G, Silvestri L, Moschese D, Ricci S, Petrozza V, et al. Serum and urine biomarkers for human renal cell carcinoma. Dis Markers. 2015;2015:251403.CrossRefPubMedPubMedCentral Pastore AL, Palleschi G, Silvestri L, Moschese D, Ricci S, Petrozza V, et al. Serum and urine biomarkers for human renal cell carcinoma. Dis Markers. 2015;2015:251403.CrossRefPubMedPubMedCentral
4.
go back to reference Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 2007;98(1):77–82.CrossRefPubMed Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 2007;98(1):77–82.CrossRefPubMed
5.
go back to reference Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara T. Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). Biochim Biophys Acta. 1997;1354(1):24–8.CrossRefPubMed Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara T. Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). Biochim Biophys Acta. 1997;1354(1):24–8.CrossRefPubMed
6.
go back to reference Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, et al. Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics. 2005;5(10):2631–40.CrossRefPubMed Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, et al. Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics. 2005;5(10):2631–40.CrossRefPubMed
7.
go back to reference Skubitz KM, Zimmermann W, Kammerer R, Pambuccian S, Skubitz AP. Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006;147(5):250–67.CrossRefPubMed Skubitz KM, Zimmermann W, Kammerer R, Pambuccian S, Skubitz AP. Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006;147(5):250–67.CrossRefPubMed
8.
go back to reference Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006;5:64.CrossRefPubMedPubMedCentral Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006;5:64.CrossRefPubMedPubMedCentral
9.
go back to reference Teratani T, Domoto T, Kuriki K, Kageyama T, Takayama T, Ishikawa A, et al. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology. 2007;69(2):236–40.CrossRefPubMed Teratani T, Domoto T, Kuriki K, Kageyama T, Takayama T, Ishikawa A, et al. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology. 2007;69(2):236–40.CrossRefPubMed
10.
go back to reference Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, et al. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer. 2009;9:248.CrossRefPubMedPubMedCentral Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, et al. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer. 2009;9:248.CrossRefPubMedPubMedCentral
11.
go back to reference Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, et al. Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE. Mol BioSyst. 2012;8(4):1040–51.CrossRefPubMed Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, et al. Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE. Mol BioSyst. 2012;8(4):1040–51.CrossRefPubMed
12.
go back to reference Feng JY, Diao XW, Fan MQ, Wang PX, Xiao Y, Zhong X, et al. Screening of feature genes of the renal cell carcinoma with DNA microarray. Eur Rev Med Pharmacol Sci. 2013;17(22):2994–3001.PubMed Feng JY, Diao XW, Fan MQ, Wang PX, Xiao Y, Zhong X, et al. Screening of feature genes of the renal cell carcinoma with DNA microarray. Eur Rev Med Pharmacol Sci. 2013;17(22):2994–3001.PubMed
13.
go back to reference Tan C, Takayama T, Takaoka N, Fujita H, Miyazaki M, Sugiyama T, Ozono S. Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival. Clin Med Insights Oncol. 2014;8:21–7.CrossRefPubMedPubMedCentral Tan C, Takayama T, Takaoka N, Fujita H, Miyazaki M, Sugiyama T, Ozono S. Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival. Clin Med Insights Oncol. 2014;8:21–7.CrossRefPubMedPubMedCentral
14.
go back to reference Zhou J, Deng Z, Chen Y, Gao Y, Wu D, Zhu G, et al. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma. Urol Oncol. 2015;33(3):113. e9-17CrossRefPubMed Zhou J, Deng Z, Chen Y, Gao Y, Wu D, Zhu G, et al. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma. Urol Oncol. 2015;33(3):113. e9-17CrossRefPubMed
15.
go back to reference Shi YE, Ni J, Xiao G, Liu YE, Fuchs A, Yu G, et al. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene. MRG Cancer Res. 1997;57(15):3084–91.PubMed Shi YE, Ni J, Xiao G, Liu YE, Fuchs A, Yu G, et al. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene. MRG Cancer Res. 1997;57(15):3084–91.PubMed
16.
go back to reference Wang M, Liu YE, Ni J, Aygun B, Goldberg ID, Shi YE. Induction of Mammary Differentiation by Mammary-derived Growth Inhibitor- related Gene That Interacts with an omega-3 Fatty Acid on Growth Inhibition of Breast Cancer Cells. Cancer Res. 2000;60(22):6482–7.PubMed Wang M, Liu YE, Ni J, Aygun B, Goldberg ID, Shi YE. Induction of Mammary Differentiation by Mammary-derived Growth Inhibitor- related Gene That Interacts with an omega-3 Fatty Acid on Growth Inhibition of Breast Cancer Cells. Cancer Res. 2000;60(22):6482–7.PubMed
17.
go back to reference Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, et al. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res. 2006;66(8):4443–9.CrossRefPubMed Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, et al. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res. 2006;66(8):4443–9.CrossRefPubMed
18.
go back to reference Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer. 2008;8:276.CrossRefPubMedPubMedCentral Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer. 2008;8:276.CrossRefPubMedPubMedCentral
19.
go back to reference Tölle A, Krause H, Miller K, Jung K, Stephan C. Importance of brain-type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. Oncol Rep. 2011;25(5):1307–12.CrossRefPubMed Tölle A, Krause H, Miller K, Jung K, Stephan C. Importance of brain-type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. Oncol Rep. 2011;25(5):1307–12.CrossRefPubMed
20.
go back to reference Liu RZ, Graham K, Glubrecht DD, Lai R, Mackey JR, Godbout R. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol. 2012;228(3):310–21.CrossRefPubMed Liu RZ, Graham K, Glubrecht DD, Lai R, Mackey JR, Godbout R. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol. 2012;228(3):310–21.CrossRefPubMed
21.
go back to reference De Rosa A, Pellegatta S, Rossi M, Tunici P, Magnoni L, Speranza MC, et al. A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One. 2012;7(12):e52113.CrossRefPubMedPubMedCentral De Rosa A, Pellegatta S, Rossi M, Tunici P, Magnoni L, Speranza MC, et al. A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One. 2012;7(12):e52113.CrossRefPubMedPubMedCentral
22.
go back to reference Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R. B-FABP-expressing radial glial cells: the malignant glioma cell of origin? Neoplasia. 2007;9(9):734–44.CrossRefPubMedPubMedCentral Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R. B-FABP-expressing radial glial cells: the malignant glioma cell of origin? Neoplasia. 2007;9(9):734–44.CrossRefPubMedPubMedCentral
23.
go back to reference Mita R, Beaulieu MJ, Field C, Godbout R. Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J Biol Chem. 2010;285(47):37005–15.CrossRefPubMedPubMedCentral Mita R, Beaulieu MJ, Field C, Godbout R. Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J Biol Chem. 2010;285(47):37005–15.CrossRefPubMedPubMedCentral
24.
go back to reference Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005;102(16):5814–9.CrossRefPubMedPubMedCentral Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005;102(16):5814–9.CrossRefPubMedPubMedCentral
25.
go back to reference Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer. 2006;6:97.CrossRefPubMedPubMedCentral Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer. 2006;6:97.CrossRefPubMedPubMedCentral
27.
go back to reference Takaoka N, Takayama T, Teratani T, Sugiyama T, Mugiya S, Ozono S. Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines. BMC Mol Biol. 2011;12:31.CrossRefPubMedPubMedCentral Takaoka N, Takayama T, Teratani T, Sugiyama T, Mugiya S, Ozono S. Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines. BMC Mol Biol. 2011;12:31.CrossRefPubMedPubMedCentral
28.
go back to reference Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol. 2007;8:47.CrossRefPubMedPubMedCentral Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol. 2007;8:47.CrossRefPubMedPubMedCentral
29.
go back to reference de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ, van Muijen GN. Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer. 2005;92(12):2249–61.CrossRefPubMedPubMedCentral de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ, van Muijen GN. Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer. 2005;92(12):2249–61.CrossRefPubMedPubMedCentral
30.
go back to reference Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J Invest Dermatol. 2010;130(1):221–9.CrossRefPubMedPubMedCentral Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J Invest Dermatol. 2010;130(1):221–9.CrossRefPubMedPubMedCentral
31.
33.
go back to reference Balendiran GK, Schnutgen F, Scapin G, Borchers T, Xhong N, Lim K, et al. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem. 2000;275(35):27045–54.PubMed Balendiran GK, Schnutgen F, Scapin G, Borchers T, Xhong N, Lim K, et al. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem. 2000;275(35):27045–54.PubMed
Metadata
Title
Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines
Authors
Naohisa Takaoka
Tatsuya Takayama
Seiichiro Ozono
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3184-x

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine